TECH / Bio-Techne Corporation - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXHCNAGE ACT OF 1934

Exhibit 4.1 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXHCNAGE ACT OF 1934 The following description of registered securities of Bio-Techne Corporation is intended as a summary only and therefore is not a complete description. As used in this “Description of Registrant’s Securities,” the terms “Bio-Techne,” “Company,” “we,” or “our” refer to Bio-Tec

Bio-Techne Insider Trading Policy Effective February 1, 2023

Exhibit 19 Bio-Techne Insider Trading Policy Effective February 1, 2023 Purpose and Scope Purpose of the Policy Insider Trading Policy (this “Policy”) describes the standards of Bio-Techne Corporation and its affiliated companies (together, the “Company”) on trading of Company securities or securities of certain other publicly traded companies while in the possession of confidential information.

Bio-Techne Corporation, a Minnesota corporation, had the material subsidiaries below as of the date of filing its Annual Report on Form 10-K for fiscal year ended June 30, 2025. Certain subsidiaries are not named because they were not significant ind

Exhibit 21 2 Bio-Techne Corporation, a Minnesota corporation, had the material subsidiaries below as of the date of filing its Annual Report on Form 10-K for fiscal year ended June 30, 2025.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

BIO-TECHNE CORPORATION Amended and Restated Policy on Recoupment of Certain Executive Incentive Compensation

Exhibit 97 BIO-TECHNE CORPORATION Amended and Restated Policy on Recoupment of Certain Executive Incentive Compensation Description Bio-Techne Corporation, a Minnesota corporation (the “Company”), has adopted this Amended and Restated Policy on Recoupment of Certain Executive Incentive Compensation (the “Policy”), effective as of June 28, 2023 (the “Effective Date”), pursuant to the requirements of Nasdaq Listing Rule 5608 and Securities Exchange Act Rule 10D-1.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 BIO-TECHNE CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Bio-Techne Releases Fourth Quarter Fiscal 2025 Results

Exhibit 99.1 Bio-Techne Releases Fourth Quarter Fiscal 2025 Results Minneapolis/August 6, 2025/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2025. Fourth Quarter FY2025 Highlights ●Fourth quarter organic revenue increased by 3% (4% reported) to $317.0 million. Full year organic revenue increased 5% (5% reported) to $1.2 billion.

BIO-TECHNE DECLARES DIVIDEND

Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND MINNEAPOLIS, August 6, 2025/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2025. The quarterly dividend will be payable August 29, 2025, to all common shareholders of record on August 18, 2025. Future cash dividends will be considered

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 000-17272 41-1427402 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 614 McKinley Place NE Minneapolis, MN 55413 (Address of

Bio-Techne Corporation Conflict Minerals Report For the Year Ended December 31, 2024

Exhibit 1.01 Bio-Techne Corporation Conflict Minerals Report For the Year Ended December 31, 2024 Introduction This Conflict Minerals Report for Bio-Techne Corporation (“Bio-Techne,” the “Company,” “we,” or “our”) is provided in accordance with Rule 13p-1 under the Securities Exchange Act of 1934 (“Rule 13p-1”) for the reporting period from January 1, 2024 to December 31, 2024. For the purposes of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025, or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 BIO-TECHNE CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS

EX-99.1 2 tech-20250507xex99d1.htm EX-99.1 Exhibit 99.1 BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS Minneapolis/May 7, 2025/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2025. Third Quarter FY2025 Highlights ●Third quarter organic revenue increased by 6% (4% reported) to $316.2 million. ●GAAP earnings per share (EPS) wa

BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM

Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM MINNEAPOLIS, May 7, 2025/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2025. The quarterly dividend will be payable May 30, 2025, to all common shareholders of record on May 19, 2025. Future cash divi

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024, or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

Bio-Techne Appoints Dr. Amy E. Herr to Board of Directors

Exhibit 99.3 Bio-Techne Appoints Dr. Amy E. Herr to Board of Directors Minneapolis, February 4, 2025 /PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Amy E. Herr, Ph.D. to serve as an independent director on the Company's Board of Directors beginning on February 1, 2025. Dr. Herr will serve on the Science & Technology Committee of the Board of Directors. Dr.

BIO-TECHNE DECLARES DIVIDEND

Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND MINNEAPOLIS, February 5, 2025/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2024. The quarterly dividend will be payable February 28, 2025, to all common shareholders of record on February 17, 2025. Future cash dividends will be c

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2025 BIO-TECHNE CORPORA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2025 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2025 RESULTS

Exhibit 99.1 BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2025 RESULTS Minneapolis/February 5, 2025/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, 2024. Second Quarter FY2025 Highlights ●Second quarter organic revenue increased by 9% (9% reported) to $297.0 million. ●GAAP earnings per share (EPS) was $0.22 versus $0.17 one year a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024, or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2025 RESULTS

Exhibit 99.1 BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2025 RESULTS Minneapolis/October 30, 2024/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September 30, 2024. First Quarter FY2025 Highlights ●First quarter organic revenue increased by 4% (5% reported) to $289.5 million. ●GAAP earnings per share (EPS) was $0.21 versus $0.31 one year ago.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

BIO-TECHNE DECLARES DIVIDEND

Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND MINNEAPOLIS, October 30, 2024/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2024. The quarterly dividend will be payable November 22, 2024, to all common shareholders of record on November 11, 2024. Future cash dividends will be

Message from our CEO A Letter to Shareholders from Robert Baumgartner, Chairman of the Board Notice of 2024 Annual Meeting of Shareholders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

COURTESY PDF OF PROXY STATEMENT

Notice of Annual Meeting of Shareholders Thursday, October 24, 2024 8:00 a.m. Central Time 2024 Proxy StatementAt Bio-Techne, we are accelerating discoveries to positively impact health by collaborating, developing, and manufacturing award- winning tools that help researchers achieve reproducible and consistent results. Our innovative products and services provide the solutions scientists need to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

Description of Capital Stock -- incorporated by reference to Exhibit 4.1 of the Company's Form 10-K dated August 22, 2024

Exhibit 4.1 DESCRIPTION OF COMMON STOCK The following summary of the common stock, par value $0.01 per share (the “Common Stock”), of Bio-Techne Corporation (the “Company,” “we,” or “our”) is based on and qualified by our Amended and Restated Articles of Incorporation (the “Articles”) and our Fourth Amended and Restated Bylaws (the “Bylaws”). For a complete description of the terms and provisions

Bio-Techne’s Policy on Recoupment of Certain Executive Incentive Compensation

Exhibit 97 BIO-TECHNE CORPORATION Amended and Restated Policy on Recoupment of Certain Executive Incentive Compensation Description Bio-Techne Corporation, a Minnesota corporation (the “Company”), has adopted this Amended and Restated Policy on Recoupment of Certain Executive Incentive Compensation (the “Policy”), effective as of June 28, 2023 (the “Effective Date”), pursuant to the requirements of Nasdaq Listing Rule 5608 and Securities Exchange Act Rule 10D-1.

Bio-Techne’s Insider Trading Policy

Exhibit 19 Bio-Techne Insider Trading Policy Effective February 1, 2023 Purpose and Scope Purpose of the Policy Insider Trading Policy (this “Policy”) describes the standards of Bio-Techne Corporation and its affiliated companies (together, the “Company”) on trading of Company securities or securities of certain other publicly traded companies while in the possession of confidential information.

Subsidiaries of the Company – incorporated by reference to Exhibit 21 of the Company’s Form 10-K dated August 22, 2024*

Exhibit 21 2 Bio-Techne Corporation, a Minnesota corporation, had the material subsidiaries below as of the date of filing its Annual Report on Form 10-K for fiscal year ended June 30, 2024.

BIO-TECHNE DECLARES DIVIDEND

Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND MINNEAPOLIS, August 7, 2024/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2024. The quarterly dividend will be payable August 30, 2024, to all common shareholders of record on August 19, 2024. Future cash dividends will be considered

BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2024 RESULTS

Exhibit 99.1 BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2024 RESULTS Minneapolis/August 7, 2024/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2024. Fourth Quarter FY2024 Highlights ●Fourth quarter organic revenue increased by 1% (2% reported) to $306.1 million. Full year organic revenue increased 1% (2% reported) to $1.2 billion.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 BIO-TECHNE CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 000-17272 41-1427402 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 614 McKinley Place NE Minneapolis, MN 55413 (Address of

Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.

Exhibit 1.01 Bio-Techne Corporation Conflict Minerals Report For the Year Ended December 31, 2023 Introduction This Conflict Minerals Report for Bio-Techne Corporation (“Bio-Techne,” the “Company,” “we,” or “our”) is provided in accordance with Rule 13p-1 under the Securities Exchange Act of 1934 (“Rule 13p-1”) for the reporting period from January 1, 2023 to December 31, 2023. For the purposes of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024, or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2024 RESULTS

Exhibit 99.1 BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2024 RESULTS Minneapolis/May 1, 2024/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2024. Third Quarter FY2024 Highlights ●Third quarter organic revenue increased by 2% (3% reported) to $303.4 million. ●GAAP earnings per share (EPS) was $0.31 versus $0.43 one year ago. Delivere

BIO-TECHNE DECLARES DIVIDEND

Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND MINNEAPOLIS, May 1, 2024/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2024. The quarterly dividend will be payable May 24, 2024, to all common shareholders of record on May 13, 2024. Future cash dividends will be considered by the B

BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS

EXHIBIT 99.1 BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS Minneapolis, April 30, 2024 /PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky will serve as a member of the Science and Technology Committee. Following the appoin

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

TECH / Bio-Techne Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Bio-Techne Corp Title of Class of Securities: Common Stock CUSIP Number: 09073M104 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Ru

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023, or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2024 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

BIO-TECHNE DECLARES DIVIDEND

Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND MINNEAPOLIS, February 1, 2024/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2023. The quarterly dividend will be payable February 26, 2024, to all common shareholders of record on February 12, 2024. Future cash dividends will be c

BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2024 RESULTS

Exhibit 99.1 BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2024 RESULTS Minneapolis/February 1, 2024/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ended December 31, 2023. Second Quarter FY2024 Highlights ●Second quarter organic revenue declined by 2% (0% reported) to $272.6 million. Organic revenue remained flat (2% reported) in the first half of f

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 BIO-TECHNE CORPORAT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

BIO-TECHNE ANNOUNCES APPOINTMENT OF MATTHEW F. McMANUS AS PRESIDENT, DIAGNOSTICS AND GENOMICS SEGMENT

EXHIBIT 99.1 BIO-TECHNE ANNOUNCES APPOINTMENT OF MATTHEW F. McMANUS AS PRESIDENT, DIAGNOSTICS AND GENOMICS SEGMENT Minneapolis/January 5, 2024/ Bio-Techne Corporation (NASDAQ: TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus succeeds Kim Kelderman, who will become Bio-Techne’s Chief Executive Officer eff

Executive Employment Agreement, dated January 4, 2024, between the Company and Matthew McManus

EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is made and entered into between Bio-Techne Corporation, a Minnesota corporation (“Bio-Techne”), and Matthew McManus (“Executive”) (each may be referred to individually as a “Party” and collectively as the “Parties”).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023, or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2024 RESULTS

Exhibit 99.1 BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2024 RESULTS Minneapolis/October 31, 2023/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September 30, 2023. First Quarter FY2024 Highlights ●First quarter organic revenue increased by 2% (3% reported) to $276.9 million. ●GAAP earnings per share1) (EPS) was $0.31 versus $0.55 one year ago

BIO-TECHNE DECLARES DIVIDEND

Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND MINNEAPOLIS, October 31, 2023/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2023. The quarterly dividend will be payable November 24, 2023, to all common shareholders of record on November 10, 2023. Future cash dividends will be

Form of Executive Employment Agreement by and between the Company and Kim Kelderman – incorporated by reference to Exhibit 10.1 of the Company’s Form 8-K dated October 19, 2023*

EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is made and entered into between Bio-Techne Corporation, a Minnesota corporation (“Bio-Techne”), and Kim Kelderman (“Executive”) (each may be referred to individually as a “Party” and collectively as the “Parties”).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2023 BIO-TECHNE CORPORA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2023 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

BIO-TECHNE APPOINTS KIM KELDERMAN AS CHIEF EXECUTIVE OFFICER

EXHIBIT 99.1 BIO-TECHNE APPOINTS KIM KELDERMAN AS CHIEF EXECUTIVE OFFICER MINNEAPOLIS, October 19, 2023 /PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) today announced that its Board of Directors appointed Kim Kelderman as President and Chief Executive Officer effective February 1, 2024. Concurrent with his role as CEO, Mr. Kelderman will also become a member of Bio-Techne’s Board of Director

Message from our CEO Notice of 2023 Annual Meeting of Shareholders Proxy Statement Summary Proposal 1: Size of the Board Proposal 2: Election of Directors Corporate Governance Director Compensation Corporate Sustainability Proposal 3. Advisory Vote o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

COURTESY PDF OF PROXY STATEMENT

Notice of Annual Meeting of Shareholders Thursday, October 26, 2023 8:00 a.m. Central Time 2023 Proxy StatementAt Bio-Techne, we are accelerating discoveries to positively impact health by collaborating, developing, and manufacturing award- winning tools that help researchers achieve reproducible and consistent results. Our innovative products and services provide the solutions scientists need to

Subsidiaries of the Company – incorporated by reference to Exhibit 21 of the Company’s Form 10-K dated August 23, 2023*

Exhibit 21 2 Bio-Techne Corporation, a Minnesota corporation, had the material subsidiaries below as of the date of filing its Annual Report on Form 10-K for fiscal year ended June 30, 2023.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

Bio-Techne’s Insider Trading Policy

Exhibit 19 Bio-Techne Insider Trading Policy Effective February 1, 2023 Purpose and Scope Purpose of the Policy Insider Trading Policy (this “Policy”) describes the standards of Bio-Techne Corporation and its affiliated companies (together, the “Company”) on trading of Company securities or securities of certain other publicly traded companies while in the possession of confidential information.

Description of Capital Stock -- attached as Exhibit 4.1 hereto

Exhibit 4.1 DESCRIPTION OF COMMON STOCK The following summary of the common stock, par value $0.01 per share (the “Common Stock”), of Bio-Techne Corporation (the “Company,” “we,” or “our”) is based on and qualified by our Amended and Restated Articles of Incorporation (the “Articles”) and our Fourth Amended and Restated Bylaws (the “Bylaws”). For a complete description of the terms and provisions

BIO-TECHNE DECLARES DIVIDEND

Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND MINNEAPOLIS, August 8, 2023/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2023. The quarterly dividend will be payable September 1, 2023, to all common shareholders of record on August 18, 2023. Future cash dividends will be considere

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2023 RESULTS

Exhibit 99.1 BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2023 RESULTS Minneapolis/August 8, 2023/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ended June 30, 2023. Fourth Quarter FY2023 Highlights ●Fourth quarter organic revenue increased by 5% (5% reported) to $301.3 million. Full year organic revenue increased 5% (3% reported) to $1.1 billion. ●

Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.

Exhibit 1.01 Bio-Techne Corporation Conflict Minerals Report For the Year Ended December 31, 2022 Introduction This Conflict Minerals Report for Bio-Techne Corporation (“Bio-Techne,” the “Company,” “we,” or “our”) is provided in accordance with Rule 13p-1 under the Securities Exchange Act of 1934 (“Rule 13p-1”) for the reporting period from January 1, 2022 to December 31, 2022. For the purposes of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter)

SD 1 tmb-20230531xsd.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 000-17272 41-1427402 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 614 McKinley Place NE Minnea

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023, or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

Press Release, dated May 3, 2023, announcing cash dividend

Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND MINNEAPOLIS, May 3, 2023/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2023. The quarterly dividend will be payable May 26, 2023, to all common shareholders of record on May 15, 2023. Future cash dividends will be considered by the B

Press Release, dated May 3, 2023, announcing results of operations

Exhibit 99.1 BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2023 RESULTS Minneapolis/May 3, 2023/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ended March 31, 2023. Third Quarter FY2023 Highlights ●Third quarter organic revenue increased by 3% (1% reported) to $294.1 million and 4% (2% reported) in the first nine months of fiscal 2023 to $835.4 million

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 BIO-TECHNE CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

BIO-TECHNE COMPLETES INVESTMENT IN WILSON WOLF MANUFACTURING

EXHIBIT 99.1 BIO-TECHNE COMPLETES INVESTMENT IN WILSON WOLF MANUFACTURING MINNEAPOLIS, April 3, 2023 /PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its investment in Wilson Wolf Manufacturing. Wilson Wolf achieved the trailing 12-month earnings before interest, taxes, depreciation, and amortization (EBITDA) target of $55 million, triggering Bio-Techne’s initi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 BIO-TECHNE CORPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

BIO-TECHNE ANNOUNCES INVESTMENT IN WILSON WOLF

EXHIBIT 99.1 BIO-TECHNE ANNOUNCES INVESTMENT IN WILSON WOLF MINNEAPOLIS, March 1, 2023 /PRNewswire/ - Bio-Techne Corporation (NASDAQ:TECH) today announced Wilson Wolf Manufacturing has met the trailing 12-month earnings before interest, taxes, depreciation, and amortization (EBITDA) target of $55 million, triggering Bio-Techne’s initial investment in the company, which is expected to close at the

***

CORRESP 1 filename1.htm February 13, 2023 Office of Life Sciences United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-7010 Re: Bio-Techne Corporation Form 10-K for the Fiscal Year Ended June 30, 2022 Filed August 24, 2022 File Number 000-17272 Dear Office of Life Sciences: This letter is written in response to the Staff’s comme

TECH / BIO-TECHNE Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0418-biotechnecorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Bio-Techne Corp. Title of Class of Securities: Common Stock CUSIP Number: 09073M104 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022, or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2023 RESULTS

Exhibit 99.1 BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2023 RESULTS Minneapolis/February 2, 2023/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ended December 31, 2022. Second Quarter FY2023 Highlights ●Second quarter organic revenue increased by 4% (1% reported) to $271.6 million and 5% (3% reported) in the first half of fiscal 2023 to $541.2 mi

BIO-TECHNE DECLARES DIVIDEND

Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND MINNEAPOLIS, February 2, 2023/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2022. The quarterly dividend will be payable February 27, 2023, to all common shareholders of record on February 13, 2023. Future cash dividends will be c

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2023 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

BIO-TECHNE ANNOUNCES RETIREMENT, APPOINTMENT OF GENERAL COUNSEL

EXHIBIT 99.1 BIO-TECHNE ANNOUNCES RETIREMENT, APPOINTMENT OF GENERAL COUNSEL Minneapolis/January 31, 2023/ Bio-Techne Corporation (NASDAQ: TECH) today announced Shane Bohnen has been appointed Senior Vice President, General Counsel effective March 3, 2023. Mr. Bohnen succeeds Brenda Furlow, who will be retiring from the Company after serving as Executive Vice President and General Counsel for the

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2023 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022, or ?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ? Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

BIO-TECHNE DECLARES CASH DIVIDEND AND STOCK DIVIDEND

? ? ? ? ? Exhibit 99.2 ? ? BIO-TECHNE DECLARES CASH DIVIDEND AND STOCK DIVIDEND ? ? MINNEAPOLIS, November 1, 2022/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2022. The quarterly dividend will be payable November 28, 2022, to all common shareholders of record on Novembe

Amended and Restated Articles of Incorporation of the Company--incorporated by reference to Exhibit 3.1 of the Company's 8-K dated November 1, 2022*

Exhibit 3.1 ? AMENDED AND RESTATED ARTICLES OF INCORPORATION OF BIO-TECHNE CORPORATION ? ARTICLE 1 ? NAME ? 1.1) The name of the corporation shall be Bio-Techne Corporation. ? ? ARTICLE 2 - REGISTERED OFFICE ? 2.1) The registered office of the corporation is located at 614 McKinley Place N.E., Minneapolis, Minnesota 55413. ? ARTICLE 3 - CAPITAL STOCK ? 3.1) Authorized Shares; Establishment of Clas

BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2023 RESULTS

Exhibit 99.1 ? BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2023 RESULTS ? Minneapolis/November 1, 2022/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September 30, 2022. ? First Quarter FY2023 Highlights ? ? First quarter organic revenue increased by 7% (5% reported) to $269.7 million. ? ? GAAP EPS was $2.21 versus $1.69 one year ago. Current y

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events, Submission of Matters to a Vote of Security Holders

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): October 27, 2022 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) ? Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

COURTESY PDF OF PROXY STATEMENT

Notice of Annual Meeting of Shareholders Thursday, October 27, 2022 8:00 a.m. Central Time 2022 Proxy StatementAt Bio-Techne, we are accelerating discoveries to positively impact health; it drives us to collaborate, develop, and manufacture award- winning tools that help researchers achieve reproducible and consistent results. Whether customers are at the cutting-edge of academic research, transla

Proxy Statement Summary Proposal 1: Size of the Board Proposal 2: Election of Directors Corporate Governance Director Compensation Corporate Sustainability Executive Compensation Proposal 3. Advisory Vote on Executive Compensation Share Information P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2022 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Amended and Restated Credit Agreement by and among the Company, the Guarantors party thereto, the Lenders party thereto, and BMO Harris Bank N.A., as Administrative Agent, dated August 31, 2022--incorporated by reference to Exhibit 10.1 of the Company's Form 8-K dated September 7, 2022*

Exhibit 10.1 Amended and Restated Credit Agreement dated as of August 31, 2022 among BIO-TECHNE CORPORATION, the Guarantors from time to time parties hereto, the Lenders from time to time parties hereto, and BMO Harris Bank N.A., as Administrative Agent and as Sustainability Structuring Agent BMO Capital Markets, JPMorgan Chase Bank N.A. and PNC Capital Markets LLC, as Joint Lead Arrangers and Joi

Proxy Statement Summary Proposal 1: Size of the Board Proposal 2: Election of Directors Corporate Governance Director Compensation Corporate Sustainability Executive Compensation Proposal 3. Advisory Vote on Executive Compensation Share Information P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

Description of Capital Stock -- incorporated by reference to Exhibit 4.1 of the Company's Form 10-K dated August 24, 2022*

Exhibit 4.1 DESCRIPTION OF COMMON STOCK ? The following summary of the common stock, par value $0.01 per share (the ?Common Stock?), of Bio-Techne Corporation (the ?Company,? ?we,? or ?our?) is based on and qualified by our Amended and Restated Articles of Incorporation (the ?Articles?) and our Third Amended and Restated Bylaws (the ?Bylaws?). For a complete description of the terms and provisions

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ? ? ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? ? For the fiscal year ended June 30, 2022, or ? ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) ? Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

Subsidiaries of the Company - incorporated by reference to Exhibit 21 of the Company's Form 10-K dated August 24, 2022*

Exhibit 21 ? 2 Bio-Techne Corporation, a Minnesota corporation, had the material subsidiaries below as of the date of filing its Annual Report on Form 10-K for fiscal year ended June 30, 2022.

BIO-TECHNE ANNOUNCES CEO TRANSITION PLAN

EX-99 2 tmb-20220804xex99.htm EX-99 Exhibit 99.1 BIO-TECHNE ANNOUNCES CEO TRANSITION PLAN MINNEAPOLIS, August 4, 2022 /PRNewswire/ - Bio-Teche Corporation (NASDAQ: TECH) today announced Chuck Kummeth’s planned two-year transition from his position as Bio-Techne’s Chief Executive Officer (CEO) effective June 30, 2024. The Company’s Board of Directors has begun its search for Mr. Kummeth’s replaceme

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Press Release, dated August 4, 2022, announcing results of operations

Exhibit 99.1 ? BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2022 RESULTS ? Minneapolis/August 4, 2022/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ended June 30, 2022. ? Fourth Quarter FY2022 Highlights ? ?Fourth quarter organic revenue increased by 14% (11% reported) to $288.2 million. Full year organic growth of 17% (19% reported) to $1.1 billio

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): August 4, 2022 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) ? Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Press Release, dated August 4, 2022, announcing cash dividend

? ? ? ? ? Exhibit 99.2 ? ? BIO-TECHNE DECLARES DIVIDEND ? ? MINNEAPOLIS, August 4, 2022/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2022. The quarterly dividend will be payable August 29, 2022, to all common shareholders of record on August 15, 2022. Future cash dividends w

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter)

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) ? Minnesota 000-17272 41-1427402 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) ? 614 McKinley Place NE Minneapolis, MN 55413 (Add

Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.

? Exhibit 1.01 Bio-Techne Corporation Conflict Minerals Report For the Year Ended December 31, 2021 Introduction This Conflict Minerals Report for Bio-Techne Corporation (?Bio-Techne,? the ?Company,? ?we,? or ?our?) is provided in accordance with Rule 13p-1 under the Securities Exchange Act of 1934 (?Rule 13p-1?) for the reporting period from January 1, 2021 to December 31, 2021. For the purposes

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022, or ?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ? Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): May 4, 2022 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) ? Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

BIO-TECHNE DECLARES DIVIDEND

? ? ? ? ? Exhibit 99.2 ? ? BIO-TECHNE DECLARES DIVIDEND ? ? MINNEAPOLIS, May 4, 2022/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended March 31, 2022. The quarterly dividend will be payable May 27, 2022, to all common shareholders of record on May 16, 2022. Future cash dividends will be c

BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2022 RESULTS

Exhibit 99.1 ? BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2022 RESULTS ? Minneapolis/May 4, 2022/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ended March 31, 2022. ? Third Quarter FY2022 Highlights ? ? Third quarter organic revenue increased by 17% (19% reported) to $290.4 million and 18% (22% reported) in the first nine months of fiscal 2022 to $

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2022 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Fourth Amended and Restated Bylaws of the Company--incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K dated April 27, 2022*

Exhibit 3.1 ? FOURTH AMENDED AND RESTATED BYLAWS OF BIO-TECHNE CORPORATION Effective April 26, 2022 Article 1.? ? OFFICES 1.1)Offices. The principal office of the corporation shall be 614 McKinley Place N.E., Minneapolis, Minnesota 55413, and the corporation may have offices at such other places within or without the State of Minnesota as the Board may designate. Article 2.? ? MEETINGS OF SHAREHOL

TECH / BIO-TECHNE Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Bio-Techne Corp. Title of Class of Securities: Common Stock CUSIP Number: 09073M104 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021, or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

Employment Agreement by and between the Company and Mr. William Geist dated December 20, 2021

Exhibit 10.18 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?) is made and entered into between Bio-Techne Corporation, a Minnesota corporation (?Bio-Techne?), and William Geist (?Employee?) (each may be referred to individually as a ?Party? and collectively as the ?Parties?). RECITALS Whereas, Bio-Techne wishes to employ Employee under the terms and conditions

BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2022 RESULTS

Exhibit 99.1 BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2022 RESULTS Minneapolis/February 1, 2022/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ended December 31, 2021. Second Quarter FY2022 Snapshot ? Second quarter organic revenue increased by 17% (20% reported) to $269.3 million and 19% (23% reported) in the first half of fiscal 2022 to $527.0

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2022 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM

Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM MINNEAPOLIS, February 1, 2022/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended December 31, 2021. The quarterly dividend will be payable February 25, 2022, to all common shareholders of record on February 11, 2022

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2021 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

BIO-TECHNE ANNOUNCES APPOINTMENT OF WILL GEIST AS PRESIDENT, PROTEIN SCIENCES SEGMENT

Exhibit. 99.1 BIO-TECHNE ANNOUNCES APPOINTMENT OF WILL GEIST AS PRESIDENT, PROTEIN SCIENCES SEGMENT Minneapolis/December 21, 2021/ Bio-Techne Corporation (NASDAQ: TECH) today announced William A. Geist has been appointed President, Protein Sciences Segment, effective January 3, 2022. Mr. Geist succeeds N. David Eansor, who will be retiring from the Company. Mr. Eansor will remain with Bio-Techne t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021, or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of (I.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2022 RESULTS

EX-99.1 2 ex300342.htm EXHIBIT 99.1 Exhibit 99.1 BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2022 RESULTS Minneapolis/November 2, 2021/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2021. First Quarter FY2022 Snapshot ● First quarter organic revenue increased by 21% (26% reported) to $257.7 million. ● GAAP EPS was $1.69 versus $0.8

BIO-TECHNE DECLARES DIVIDEND

EX-99.2 3 ex300343.htm EXHIBIT 99.2 Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND MINNEAPOLIS, November 2, 2021/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2021. The quarterly dividend will be payable November 26, 2021 to all common shareholders of record on November 12, 2

Submission of Matters to a Vote of Security Holders

SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party Other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party Other than the Registrant ?? Check the appropriate box: ??? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?

TECH / BIO-TECHNE Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Bio-Techne Corp. Title of Class of Securities: Common Stock CUSIP Number: 09073M104 Date of Event Which Requires Filing of this Statement: August 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule

Subsidiaries of the Company

Exhibit 21 Bio-Techne Corporation, a Minnesota corporation, had the material subsidiaries below as of the date of filing its Annual Report on Form 10-K for fiscal year ended June 30, 2021.

Form of Performance Vesting Incentive Stock Option Agreement - incorporated by reference to Exhibit 10.10 of the Company's Form 10-K dated August 25, 2021*

EX-10.10 10 ex248811.htm EXHIBIT 10.10 Exhibit 10.10 INCENTIVE STOCK OPTION AGREEMENT (PERFORMANCE VESTING) BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a

Form of Performance Vesting Restricted Stock Award Agreement - incorporated by reference to Exhibit 10.4 of the Company's Form 10-K dated August 25, 2021*

Exhibit 10.4 RESTRICTED STOCK AWARD AGREEMENT (PERFORMANCE VESTING) BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [?], by and between Bio-Techne Corporation, a Minnesota corporation (the ?Company?), and [?] (?Participant?). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee, officer, director of or c

Description of Capital Stock -- incorporated by reference to Exhibit 4.1 of the Company's Form 10-K dated August 25, 2021*

Exhibit 4.1 DESCRIPTION OF COMMON STOCK The following summary of the common stock, par value $0.01 per share (the ?Common Stock?), of Bio-Techne Corporation (the ?Company,? ?we,? or ?our?) is based on and qualified by our Amended and Restated Articles of Incorporation (the ?Articles?) and our Third Amended and Restated Bylaws (the ?Bylaws?). For a complete description of the terms and provisions o

Form of the Time Vesting Performance Unit Award Agreement - incorporated by reference to Exhibit 10.7 of the Company's Form 10-K dated August 25, 2021*

Exhibit 10.7 PERFORMANCE UNIT AGREEMENT (TIME VESTING) BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [?], by and between Bio-Techne Corporation, a Minnesota corporation (the ?Company?), and [?] (?Participant?). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or

Form of Performance Vesting Restricted Stock Unit Award Agreement - incorporated by reference to Exhibit 10.6 of the Company's Form 10-K dated August 25, 2021*

Exhibit 10.6 RESTRICTED STOCK UNIT AGREEMENT (PERFORMANCE VESTING) BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [?], by and between Bio-Techne Corporation, a Minnesota corporation (the ?Company?), and [?] (?Participant?). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee, officer, director of or co

Form of Time Vesting Restricted Stock Unit Award Agreement - incorporated by reference to Exhibit 10.5 of the Company's Form 10-K dated August 25, 2021*

Exhibit 10.5 GLOBAL RESTRICTED STOCK UNIT AGREEMENT BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [?], by and between Bio-Techne Corporation, a Minnesota corporation (the ?Company?), and [?] (?Participant?). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or adv

Form of Time Vesting Restricted Stock Award Agreement - incorporated by reference to Exhibit 10.3 of the Company's Form 10-K dated August 25, 2021*

Exhibit 10.3 RESTRICTED STOCK AWARD AGREEMENT (TIME VESTING) BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [?], by and between Bio-Techne Corporation, a Minnesota corporation (the ?Company?), and [?] (?Participant?). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee, officer, director of or consulta

Form of Employee Non-Qualified Stock Option Agreement - incorporated by reference to Exhibit 10.11 of the Company's Form 10-K dated August 25, 2021*

Exhibit 10.11 GLOBAL EMPLOYEE NONQUALIFIED STOCK OPTION AGREEMENT BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [?], by and between Bio-Techne Corporation, a Minnesota corporation (the ?Company?), and [?] (?Participant?). W I T N E S E T H: WHEREAS, Participant on the date hereof is a key employee or officer of the Company or o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021, or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

Form of Performance Vesting Performance Unit Award Agreement - incorporated by reference to Exhibit 10.8 of the Company's Form 10-K dated August 25, 2021*

Exhibit 10.8 PERFORMANCE UNIT AGREEMENT BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [?], by and between Bio-Techne Corporation, a Minnesota corporation (the ?Company?), and [?] (?Participant?). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or advisor to the

Form of Time Vesting Incentive Stock Option Agreement - incorporated by reference to Exhibit 10.9 of the Company's Form 10-K dated August 25, 2021*

Exhibit 10.9 INCENTIVE STOCK OPTION AGREEMENT (TIME VESTING) BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [?], by and between Bio-Techne Corporation, a Minnesota corporation (the ?Company?), and [?] (?Participant?). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee or officer of the Company or one

BIO-TECHNE DECLARES DIVIDEND

EX-99.2 3 ex271736.htm EXHIBIT 99.2 Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND MINNEAPOLIS, August 5, 2021/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2021. The quarterly dividend will be payable August 27, 2021 to all common shareholders of record on August 16, 2021. Future

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2021 RESULTS

EX-99.1 2 ex271735.htm EXHIBIT 99.1 Exhibit 99.1 BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2021 RESULTS Minneapolis/August 5, 2021/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ended June 30, 2021. Fourth Quarter FY2021 Snapshot ● Fourth quarter organic revenue increased by 39% (47% reported) to $259.0 million. Full year organic growth of 22% (26

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 000-17272 41-1427402 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 614 McKinley Place NE Minneapolis, MN 55413 (Address of

Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.

Exhibit 1.01 Bio-Techne Corporation Conflict Minerals Report For the Year Ended December 31, 2020 Introduction This Conflict Minerals Report for Bio-Techne Corporation (“Bio-Techne,” the “Company,” “we,” or “our”) is provided in accordance with Rule 13p-1 under the Securities Exchange Act of 1934 (“Rule 13p-1”) for the reporting period from January 1, 2020 to December 31, 2020. For the purposes of

Quarterly Report - FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021, or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2021 RESULTS

EX-99.1 2 ex246066.htm EXHIBIT 99.1 Exhibit 99.1 BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2021 RESULTS Minneapolis/May 6, 2021/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ended March 31, 2021. Third Quarter FY2021 Snapshot ● Third quarter organic revenue increased by 22% (25% reported) to $243.6 million and 17% (19% reported) in the first nine m

BIO-TECHNE DECLARES DIVIDEND

EX-99.2 3 ex246067.htm EXHIBIT 99.2 Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND MINNEAPOLIS, May 6, 2021/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended March 31, 2021. The quarterly dividend will be payable May 28, 2021 to all common shareholders of record on May 17, 2021. Future cash di

***

614 McKinley Place NE Minneapolis, MN 55413 P: 612-379-2956 March 29, 2021 Office of Life Sciences United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Bio-Techne Corp. Title of Class of Securities: Common Stock CUSIP Number: 09073M104 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Ru

Quarterly Report - FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2021 RESULTS

EX-99.1 2 ex223595.htm EXHIBIT 99.1 Exhibit 99.1 BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2021 RESULTS Minneapolis/February 2, 2021/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2020. Second Quarter FY2021 Snapshot ● Second quarter organic revenue increased by 19% (21% reported) to $224.3 million and 15% (16% reported) in the

BIO-TECHNE DECLARES DIVIDEND

EX-99.2 3 ex223596.htm EXHIBIT 99.2 Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND MINNEAPOLIS, February 2, 2021/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended December 31, 2020. The quarterly dividend will be payable February 26, 2021 to all common shareholders of record on February 12, 20

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2021 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Quarterly Report - FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of (I.

- FORM S-8

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of 1933 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 41-1427402 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification Number) 614 McKinley Place N.E. Minneapolis, Minnesota 55413-2610 (Ad

BIO-TECHNE DECLARES DIVIDEND

Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND MINNEAPOLIS, November 5, 2020/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2020. The quarterly dividend will be payable November 27, 2020 to all common shareholders of record on November 16, 2020. Future cash dividends will be c

BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2021 RESULTS

Exhibit 99.1 BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2021 RESULTS Minneapolis/November 5, 2020/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2020. First Quarter FY2021 Snapshot ● First quarter organic revenue increased by 10% (11% reported) to $204.2 million. ● GAAP EPS was $0.83 versus $0.37 one year ago. Delivered adjusted e

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Form of Director Non-Qualified Stock Option Agreement – incorporated by reference to Exhibit 10.2 of the Company’s Form 8-k dated November 3, 2020*

EX-10.2 3 ex211287.htm EXHIBIT 10.2 Exhibit 10.2 NONQUALIFIED STOCK OPTION AGREEMENT BIO-TECHNE CORPORATION 2020 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a non-employee director of the Company; and WHEREAS, the

Bio-Techne 2020 Equity Incentive Plan – incorporated by reference to Exhibit 10.1 of the Company’s Form 8-k dated November 3, 2020*

Exhibit 10.1 BIO-TECHNE CORPORATION 2020 EQUITY INCENTIVE PLAN SECTION 1. DEFINITIONS As used herein, the following terms shall have the meanings indicated below: (a) “Administrator” shall mean the Board of Directors of the Company, or one or more Committees appointed by the Board of Directors, as the case may be. (b) “Affiliate(s)” shall mean a Parent or Subsidiary of the Company. (c) “Agreement”

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders - FORM 8-K

SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2020 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Form of Time Vesting Restricted Stock Agreement– incorporated by reference to Exhibit 10.10 of the Company’s Form 8-k dated November 3, 2020*

Exhibit 10.10 RESTRICTED STOCK AWARD AGREEMENT (TIME VESTING) BIO-TECHNE CORPORATION 2020 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or advisor to the Compan

Form of Time Vesting Incentive Stock Option Agreement– incorporated by reference to Exhibit 10.8 of the Company’s Form 8-k dated November 3, 2020*

Exhibit 10.8 INCENTIVE STOCK OPTION AGREEMENT (TIME VESTING) BIO-TECHNE CORPORATION 2020 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee or officer of the Company or one of its Subsidiaries; and WHE

Form of Performance Vesting Restricted Stock Unit Agreement– incorporated by reference to Exhibit 10.7 of the Company’s Form 8-k dated November 3, 2020*

Exhibit 10.7 RESTRICTED STOCK UNIT AGREEMENT (Performance Vesting) BIO-TECHNE CORPORATION 2020 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or advisor to the C

Form of Time Vesting Cash Unit Agreement– incorporated by reference to Exhibit 10.9 of the Company’s Form 8-k dated November 3, 2020*

Exhibit 10.9 PERFORMANCE UNIT AGREEMENT (TIME VESTING) BIO-TECHNE CORPORATION 2020 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or advisor to the Company or on

Form of Time Vesting Restricted Stock Unit Agreement– incorporated by reference to Exhibit 10.11 of the Company’s Form 8-k dated November 3, 2020*

Exhibit 10.11 GLOBAL RESTRICTED STOCK UNIT AGREEMENT BIO-TECHNE CORPORATION 2020 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or advisor to the Company or one

Form of Performance Vesting Incentive Stock Option Agreement– incorporated by reference to Exhibit 10.5 of the Company’s Form 8-k dated November 3, 2020*

Exhibit 10.5 INCENTIVE STOCK OPTION AGREEMENT (Performance Vesting) BIO-TECHNE CORPORATION 2020 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee or officer of the Company or one of its Subsidiaries;

Form of Performance Vesting Restricted Stock Agreement– incorporated by reference to Exhibit 10.6 of the Company’s Form 8-k dated November 3, 2020*

Exhibit 10.6 RESTRICTED STOCK AWARD AGREEMENT (PERFORMANCE VESTING) BIO-TECHNE CORPORATION 2020 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or advisor to the

Form of Performance Vesting Cash Unit Agreement– incorporated by reference to Exhibit 10.4 of the Company’s Form 8-k dated November 3, 2020*

EX-10.4 5 ex211289.htm EXHIBIT 10.4 Exhibit 10.4 PERFORMANCE UNIT AGREEMENT BIO-TECHNE CORPORATION 2020 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or advisor

Form of Employee Non-Qualified Stock Option Agreement (Global) – incorporated by reference to Exhibit 10.3 of the Company’s Form 8-k dated November 3, 2020*

Exhibit 10.3 GLOBAL EMPLOYEE NONQUALIFIED STOCK OPTION AGREEMENT BIO-TECHNE CORPORATION 2020 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S E T H: WHEREAS, Participant on the date hereof is a key employee or officer of the Company or one of its Subsidiaries; and W

- FORM DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party Other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

- FORM DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party Other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Stat

Form of Time Vesting Incentive Stock Option Agreement. .

Exhibit 10.9 INCENTIVE STOCK OPTION AGREEMENT (TIME VESTING) BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee or officer of the Company or one

Annual Report - FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2020, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

Form of Performance Vesting Incentive Stock Option Agreement.

Exhibit 10.10 INCENTIVE STOCK OPTION AGREEMENT (PERFORMANCE VESTING) BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee or officer of the Company

Description of Capital Stock -- attached as Exhibit 4.1 hereto

Exhibit 4.1 DESCRIPTION OF COMMON STOCK The following summary of the common stock, par value $0.01 per share (the “Common Stock”), of Bio-Techne Corporation (the “Company,” “we,” or “our”) is based on and qualified by our Amended and Restated Articles of Incorporation (the “Articles”) and our Third Amended and Restated Bylaws (the “Bylaws”). For a complete description of the terms and provisions o

Form of Employee Non-Qualified Stock Option Agreement.

EX-10.11 11 ex200249.htm EXHIBIT 10.11 Exhibit 10.11 GLOBAL EMPLOYEE NONQUALIFIED STOCK OPTION AGREEMENT BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S E T H: WHEREAS, Participant on the date hereof is a key

Form of Performance Vesting Performance Unit Award Agreement.

EX-10.8 8 ex200246.htm EXHIBIT 10.8 Exhibit 10.8 PERFORMANCE UNIT AGREEMENT BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee, officer, director

Subsidiaries of the Company - incorporated by reference to Exhibit 21 of the Company's Form 10-K dated August 25, 2021*

EX-21 12 ex187163.htm EXHIBIT 21 Exhibit 21 Bio-Techne Corporation, a Minnesota corporation, had the material subsidiaries below as of the date of filing its Annual Report on Form 10-K for fiscal year ended June 30, 2020. Certain subsidiaries are not named because they were not significant individually or in the aggregate as of such date. Bio-Techne Corporation is not a subsidiary of any other ent

Form of Time Vesting Restricted Stock Unit Award Agreement.

Exhibit 10.5 GLOBAL RESTRICTED STOCK UNIT AGREEMENT BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or adv

Form of Time Vesting Restricted Stock Award Agreement.

Exhibit 10.3 RESTRICTED STOCK AWARD AGREEMENT (TIME VESTING) BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee, officer, director of or consulta

Form of the Time Vesting Performance Unit Award Agreement.

Exhibit 10.7 PERFORMANCE UNIT AGREEMENT (TIME VESTING) BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or

Form of Performance Vesting Restricted Stock Award Agreement.

Exhibit 10.4 RESTRICTED STOCK AWARD AGREEMENT (PERFORMANCE VESTING) BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee, officer, director of or c

Form of Performance Vesting Restricted Stock Unit Award Agreement.

EX-10.6 6 ex200244.htm EXHIBIT 10.6 Exhibit 10.6 RESTRICTED STOCK UNIT AGREEMENT (Performance Vesting) BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key

BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2020 RESULTS

Exhibit 99.1 BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2020 RESULTS Minneapolis/August 4, 2020/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ended June 30, 2020. Fourth Quarter FY2020 Snapshot ● Fourth quarter organic revenue decreased 8% (-8% reported) to $175.8 million. Full year organic growth of 4% (4% reported) to $738.7 million. ● GAAP EPS

BIO-TECHNE ANNOUNCES APPPOINTMENT OF JULIE L. BUSHMAN TO ITS BOARD OF DIRECTORS

EX-99.3 4 ex196411.htm EXHIBIT 99.3 Exhibit 99.3 BIO-TECHNE ANNOUNCES APPPOINTMENT OF JULIE L. BUSHMAN TO ITS BOARD OF DIRECTORS MINNEAPOLIS, August 3, 2020 /PRNewswire/ - Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Julie L. Bushman to serve as an independent director on the company's board of directors, effective July 31, 2020. Following the appointment, the board of B

BIO-TECHNE DECLARES DIVIDEND

Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND MINNEAPOLIS, August 4, 2020/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2020. The quarterly dividend will be payable August 28, 2020 to all common shareholders of record on August 18, 2020. Future cash dividends will be considered b

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

- FORM SD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 000-17272 41-1427402 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 614 McKinley Place NE Minneapolis, MN 55413 (Address of

Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.

Exhibit 1.01 Bio-Techne Corporation Conflict Minerals Report For the Year Ended December 31, 2019 Introduction This Conflict Minerals Report for Bio-Techne Corporation (“Bio-Techne,” the “Company,” “we,” or “our”) is provided in accordance with Rule 13p-1 under the Securities Exchange Act of 1934 (“Rule 13p-1”) for the reporting period from January 1, 2019 to December 31, 2019. For the purposes of

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2020 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Development, Supply and Commercialization Agreement by and between the Company and Kantaro Biosciences, LLC dated May 18, 2020 (portions of which have been redacted as noted, subject to confidential treatment) – incorporated by reference to Exhibit 10.1 of the Company's Form 8-K dated May 19, 2020*

EX-10.1 2 ex187264.htm EXHIBIT 10.1 EXHIBIT 10.1 Certain information identified by [******] in certain sections of the Agreement and attached Schedules are redacted because they contain information that is commercially sensitive, not material and would be competitively harmful if publicly disclosed. DEVELOPMENT, SUPPLY AND COMMERCIALIZATION AGREEMENT This Development, Supply and Commercialization

BIO-TECHNE AND KANTARO BIOSCIENCES ANNOUNCE PARTNERSHIP TO DEVELOP AND SCALE PRODUCTION OF COVID-19 SEROLOGY TEST

Exhibit 99.1 BIO-TECHNE AND KANTARO BIOSCIENCES ANNOUNCE PARTNERSHIP TO DEVELOP AND SCALE PRODUCTION OF COVID-19 SEROLOGY TEST MINNEAPOLIS and NEW YORK, May 19, 2020 /PRNewswire/ - Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced a partnership to initiate scaled manufacturing and

Form of Amendment No. 1 to Executive Employment Agreement – incorporated by reference to Exhibit 10.15 of the Company’s Form 10-Q dated May 11, 2020*

Exhibit 10.15 AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT This Amendment No. 1 to [Amended and Restated] Executive Employment Agreement (“Amendment”) is made by and between Bio-Techne Corporation (“Bio-Techne”) and [ ] (“Executive”), effective [ ], 2020. RECITALS WHEREAS, Bio-Techne and Executive are parties to an existing [Amended and Restated] Executive Employment Agreement, dated effectiv

Quarterly Report - FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2020 RESULTS

EX-99.1 2 ex183437.htm EXHIBIT 99.1 Exhibit 99.1 BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2020 RESULTS Minneapolis/April 30, 2020/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ended March 31, 2020. Third Quarter FY2020 Snapshot ● Third quarter organic revenue increased by 6% (5% reported) to $194.7 million and 8% (8% reported) in the first three q

BIO-TECHNE DECLARES DIVIDEND

Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND MINNEAPOLIS, April 30, 2020/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended March 31, 2020. The quarterly dividend will be payable May 22, 2020 to all common shareholders of record on May 11, 2020. Future cash dividends will be considered by the

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2020 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

TECH / Bio-Techne Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Bio-Techne Corp Title of Class of Securities: Common Stock CUSIP Number: 09073M104 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rul

Quarterly Report - FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2020 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2020 RESULTS

Exhibit 99.1 BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2020 RESULTS Minneapolis/February 4, 2020/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2019. Second Quarter FY2020 Snapshot ● Second quarter organic revenue increased by 6% (6% reported) to $184.9 million and 9% (9% reported) in the first half of fiscal 2020 to $368.2 mill

BIO-TECHNE DECLARES DIVIDEND

Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND MINNEAPOLIS, February 4, 2020/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended December 31, 2019. The quarterly dividend will be payable February 28, 2020 to all common shareholders of record on February 14, 2020. Future cash dividends will be co

Annual Report - FORM 10-K/A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K Amendment No.

Quarterly Report - FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2019 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2020 RESULTS

Exhibit 99.1 BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2020 RESULTS Minneapolis/October 29, 2019/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2019. First Quarter FY2020 Snapshot ● First quarter organic revenue increased by 13% (12% reported) to $183.2 million. ● GAAP EPS was $0.37 versus $0.45 one year ago. Delivered adjusted e

BIO-TECHNE DECLARES DIVIDEND

Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND MINNEAPOLIS, October 29, 2019/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2019. The quarterly dividend will be payable November 22, 2019 to all common shareholders of record on November 8, 2019. Future cash dividends will be co

Annual Report - FORM 10-K/A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K Amendment No.

TECH / Bio-Techne Corp DEFA14A - - FORM DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party Other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

TECH / Bio-Techne Corp DEF 14A - - FORM DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party Other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Stat

Form of Incentive Stock Option Agreement for Second Amended and Restated 2010 Equity Incentive Plan-- incorporated by reference to Exhibit 10.6 of the Company’s Form 10-K dated August 28, 201*9

Exhibit 10.6 INCENTIVE STOCK OPTION AGREEMENT BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee or officer of the Company or one of its Subsidia

Form of the Performance Unit Award Agreement for Second Amended and Restated 2010 Equity Incentive Plan incorporated by reference to Exhibit 10.5 of the Company’s Form 10-K dated August 28, 2019*

Exhibit 10.5 PERFORMANCE UNIT AGREEMENT BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or advisor to the

Form of Restricted Stock Unit Award Agreement for Second Amended and Restated 2010 Equity Incentive Plan incorporated by reference to Exhibit 10.4 of the Company’s Form 10-K dated August 28, 2019*

Exhibit 10.4 RESTRICTED STOCK UNIT AGREEMENT BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or advisor to

Subsidiaries of the Company - incorporated by reference to Exhibit 21 of the Company's Form 10-K dated August 28, 2019*

Exhibit 21 Bio-Techne Corporation, a Minnesota corporation, had the material subsidiaries below as of the date of filing its Annual Report on Form 10-K for fiscal year ended June 30, 2019.

Annual Report - FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2019, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

Form of Employee Non-Qualified Stock Option Agreement for Second Amended and Restated 2010 Equity Incentive Plan--incorporated by reference to Exhibit 10.7 of the Company’s Form 10-K dated August 28, 2019*

Exhibit 10.7 EMPLOYEE NONQUALIFIED STOCK OPTION AGREEMENT BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee or officer of the Company or one of

BIO-TECHNE DECLARES DIVIDEND

Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND MINNEAPOLIS, August 6, 2019/PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2019. The quarterly dividend will be payable August 30, 2019 to all common shareholders of record on August 16, 2019. Future cash dividends will be considered b

BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2019 RESULTS

EX-99.1 2 ex153184.htm EXHIBIT 99.1 Exhibit 99.1 BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2019 RESULTS Minneapolis/August 6, 2019/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ended June 30, 2019. Fourth Quarter FY2019 Snapshot ● Fourth quarter organic growth of 7% (6% reported) to $191.7 million. Full year organic growth of 10% (11% reported) t

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2019 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2019 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Bio-Techne Appoints Rupert Vessey to Board of Directors

Exhibit 99.1 Bio-Techne Appoints Rupert Vessey to Board of Directors MINNEAPOLIS, June 25, 2019/PRNewswire/ - Bio-Techne Corporation today announced the appointment of Dr. Rupert Vessey to the company’s Board of Directors as an independent director. Dr. Vessey’s appointment brings the total number of Bio-Techne Board members to nine. Rupert Vessey, MA, BM BCh, FRCP, DPhil is currently the Presiden

TECH / Bio-Techne Corp SD - - FORM SD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 000-17272 41-1427402 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 614 McKinley Place NE Minneapolis, MN 55413 (Address of

Bio-Techne Corporation Conflict Minerals Report For the Year Ended December 31, 2018

Exhibit 1.01 Bio-Techne Corporation Conflict Minerals Report For the Year Ended December 31, 2018 Introduction This Conflict Minerals Report for Bio-Techne Corporation (“Bio-Techne,” the “Company,” “we,” or “our”) is provided in accordance with Rule 13p-1 under the Securities Exchange Act of 1934 (“Rule 13p-1”) for the reporting period from January 1, 2018 to December 31, 2018. For the purposes of

TECH / Bio-Techne Corp 10-Q Quarterly Report FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2019 RESULTS

Exhibit 99.1 BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2019 RESULTS Minneapolis/April 30, 2019/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ended March 31, 2019. Third Quarter FY2019 Snapshot ● Third quarter organic growth of 14% (13% reported) with revenue of $184.9 million. ● GAAP EPS was $1.15 vs. $0.52 one year ago. Delivered adjusted earnings

* * * * * * * * * * * * * *

EX-99.2 3 ex142103.htm EXHIBIT 99.2 Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND Minneapolis/April 30, 2019/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended March 31, 2019. The quarterly dividend will be payable May 24, 2019 to all common shareholders of record on May 10, 2019. Future cash dividends w

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2019 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

CCXI / ChemoCentryx, Inc. / Bio-techne Corp - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ChemoCentryx, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 16383L106 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w

TECH / Bio-Techne Corp / BROWN CAPITAL MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 6)* Bio-Techne Corporation (Name of Issuer) Common Stock, Par Value $0.01 (Title of Class of Securities) 09073M104 (CUSIP Number) Eddie C. Brown Brown Capital

TECH / Bio-Techne Corp / VANGUARD GROUP INC Passive Investment

biotechnecorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6 )* Name of issuer: Bio-Techne Corp Title of Class of Securities: Common Stock CUSIP Number: 09073M104 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the appropriate box to des

TECH / Bio-Techne Corp FORM 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2018, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2019 RESULTS

Exhibit 99.1 BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2019 RESULTS Minneapolis/February 5, 2019/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2018. Second Quarter FY2019 Snapshot ● Second quarter organic revenue increased by 11% (13% reported) to $174.5 million. ● GAAP EPS was $0.45 vs. $1.29 one year ago. Current Year GAAP EP

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2019 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

* * * * * * * * * * * * * *

Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND Minneapolis/February 5, 2019/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended December 31, 2018. The quarterly dividend will be payable March 1, 2019 to all common shareholders of record on February 15, 2019. Future cash dividends will be considered by the

TECH / Bio-Techne Corp FORM S-8

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of 1933 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 41-1427402 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification Number) 614 McKinley Place N.E. Minneapolis, Minnesota 55413-2610 (Ad

TECH / Bio-Techne Corp FORM 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of incorporation or organization) (I.

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2018 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

* * * * * * * * * * * * * *

EX-99.2 3 ex126814.htm EXHIBIT 99.2 Exhibit 99.2 BIO-TECHNE DECLARES DIVIDEND Minneapolis/October 30, 2018/ - Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2018. The quarterly dividend will be payable November 23, 2018 to all common shareholders of record on November 9, 2018. Future c

BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2019 RESULTS

Exhibit 99.1 BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2019 RESULTS Minneapolis/October 30, 2018/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2018. First Quarter FY2019 Snapshot ● First quarter organic revenue increased by 10% (13% reported) to $163.0 million. ● GAAP EPS was $0.45 versus $0.42 one year ago, an increase of 7% ov

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2018 BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter) Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Amendment to the Bio-Techne Corporation Second Amended and Restated 2010 Equity Incentive Plan, incorporated by reference to Exhibit 10.1 the Company’s 8-K filed with the Securities and Exchange Commission on October 26, 2018.

EXHIBIT 10.1 BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN SECTION 1. DEFINITIONS As used herein, the following terms shall have the meanings indicated below: (a) “Administrator” shall mean the Board of Directors of the Company, or one or more Committees appointed by the Board of Directors, as the case may be. (b) “Affiliate(s)” shall mean a Parent or Subsidiary of

Form of Employee NonQualified Stock Option Agreement for Second Amended and Restated 2010 Equity Incentive Plan.

EXHIBIT 10.3 EMPLOYEE NONQUALIFIED STOCK OPTION AGREEMENT BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee or officer of the Company or one of

Form of Restricted Stock Award Agreement for Second Amended and Restated 2010 Equity Incentive Plan.

EXHIBIT 10.6 RESTRICTED STOCK AWARD AGREEMENT BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or advisor t

Form of Restricted Stock Unit Agreement for Second Amended and Restated 2010 Equity Incentive Plan.

EXHIBIT 10.7 RESTRICTED STOCK UNIT AGREEMENT BIO-TECHNE CORPORATION SECOND AMENDED AND RESTATED 2010 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or advisor to